Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Why Apellis (APLS) Might Surprise This Earnings Season
10:30am, Friday, 23'rd Feb 2024
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 20'th Feb 2024
Apellis Pharmaceuticals, Inc. (APLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
07:00am, Tuesday, 20'th Feb 2024
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
10:41am, Wednesday, 14'th Feb 2024
Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
11:06am, Tuesday, 13'th Feb 2024
Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
09:50am, Monday, 29'th Jan 2024
Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-rela
Apellis (APLS): Strong Industry, Solid Earnings Estimate Revisions
09:47am, Friday, 12'th Jan 2024
Apellis (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues
11:16am, Tuesday, 09'th Jan 2024
Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.
Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?
06:46am, Tuesday, 09'th Jan 2024
Apellis Pharmaceuticals, Inc. (APLS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into furthe
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Mo
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA
09:46am, Friday, 15'th Dec 2023
The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.
Apellis Pharmaceuticals expects European regulators to reject eye disease drug, sending shares lower
11:39am, Thursday, 14'th Dec 2023
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares fell more than 22% after it said it expects European regulators to reject its therapeutic intravitreal pegcetacoplan for the eye disease geographic atr
Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in Europe
07:15am, Thursday, 14'th Dec 2023
Apellis Pharmaceuticals Inc.'s stock APLS, +1.81% tumbled 14% early Thursday, after the company said it's been informed of a negative trend vote on the European marketing authorization application (MA
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
12:02pm, Monday, 04'th Dec 2023
Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?
12:50pm, Friday, 01'st Dec 2023
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
